|
Steatohepatitis
|
0.120 |
AlteredExpression
|
disease |
BEFREE |
RESULTS; Expression of PEPCK was higher in steatohepatitis compared with steatosis alone and normal liver, and it was correlated with the homeostasis model assessment of insulin resistance (HOMA-IR) index.
|
18316359 |
2008 |
|
Steatohepatitis
|
0.120 |
GeneticVariation
|
disease |
BEFREE |
The new transgenic strain of SHR overexpressing a dominant-positive form of human SREBP-1a under control of the phosphoenolpyruvate carboxykinase (PEPCK) promoter exhibited marked hepatic steatosis with major biochemical features of the metabolic syndrome, including hyperglycemia, hyperinsulinemia, and hypertriglyceridemia.
|
15809359 |
2005 |
|
Fatty Liver
|
0.110 |
GeneticVariation
|
disease |
BEFREE |
The new transgenic strain of SHR overexpressing a dominant-positive form of human SREBP-1a under control of the phosphoenolpyruvate carboxykinase (PEPCK) promoter exhibited marked hepatic steatosis with major biochemical features of the metabolic syndrome, including hyperglycemia, hyperinsulinemia, and hypertriglyceridemia.
|
15809359 |
2005 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.080 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to identify genetic polymorphisms in potential candidate genes for type 2 diabetes by sequencing all exons in the PCK genes (PCK1 and PCK2), and examining the association with type 2 diabetes and diabetic phenotypes in a Korean population (775 type 2 diabetic patients and 316 normal control subjects).
|
16132948 |
2005 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
Since these are the major regulatory hormones controlling glucose homeostasis, and because increased hepatic glucose production is one of the characteristics of non-insulin dependent diabetes mellitus (NIDDM), investigators have speculated that the regulation of PEPCK gene expression may be defective in patients with NIDDM.
|
8547315 |
1995 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.080 |
Biomarker
|
disease |
BEFREE |
In a conclusion, CA can regulate glucose and lipid metabolic adaptation in T2D like HepG2, zebrafish and rat models partly through reducing inflammation and oxidative stress and suppressing PEPCK.
|
30867526 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
The present data suggest that, in a German Caucasian population, the -232C/G polymorphism of the PEPCK gene is not associated with Type 2 diabetes.
|
16620271 |
2006 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
For example, the expression of two hepatic genes, glucose-6-phosphatase and PEPCK, is normally inhibited by insulin, but in type 2 diabetes, their expression is insensitive to insulin.
|
11334436 |
2001 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
This result suggests that mutations in cis-acting PEPCK gene regulatory elements do not constitute a common cause of noninsulin-dependent diabetes mellitus.
|
8636258 |
1996 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
Accordingly, the single-base variant at position - 232 of the PEPCK gene promoter is most probably not a major contributor to the pathogenesis of type 2 diabetes.
|
12916001 |
2003 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
In this study, we generated transgenic dogs expressing the phosphoenolpyruvate carboxykinase (PEPCK) gene, which is closely involved in the pathogenesis of type 2 diabetes mellitus.
|
22580743 |
2012 |
|
Diabetes
|
0.050 |
Biomarker
|
disease |
BEFREE |
PCK1 and PCK2 as candidate diabetes and obesity genes.
|
17709878 |
2007 |
|
Diabetes
|
0.050 |
Biomarker
|
disease |
BEFREE |
To employ hepatocytes as surrogate beta-cells for gene therapy of diabetes, a regulatory system was devised in this study by placing the human insulin cDNA under the control of the phosphoenolpyruvate carboxykinase (PEPCK) promoter, followed by the cytomegalovirus immediate early promoter-driven enhanced-green-fluorescent-protein open reading frame.
|
11277867 |
2001 |
|
Diabetes
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
These results provide evidence for the interaction of insulin and glucocorticoid regulatory elements in the control of PEPCK gene transcription and suggest an important role of glucocorticoids as a gluconeogenic activator during diabetes.
|
7685354 |
1993 |
|
Diabetes
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
To test the hypothesis that mutations of the PEPCK gene promoter contribute to the increased hepatic glucose production that leads to diabetes, we screened for polymorphisms of the PEPCK promoter region in 252 Japanese type 2 diabetic patients and 188 non-diabetic control subjects.
|
12916001 |
2003 |
|
Diabetes
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
The expression of the PEPCK gene in rat and human small intestine and the effect of streptozotocin-induced diabetes and fasting have been studied using reverse transcriptase-polymerase chain reaction, Northern blot analysis, and determination of enzyme activity.
|
10909974 |
2000 |
|
Diabetes Mellitus
|
0.050 |
AlteredExpression
|
group |
BEFREE |
These results provide evidence for the interaction of insulin and glucocorticoid regulatory elements in the control of PEPCK gene transcription and suggest an important role of glucocorticoids as a gluconeogenic activator during diabetes.
|
7685354 |
1993 |
|
Diabetes Mellitus
|
0.050 |
AlteredExpression
|
group |
BEFREE |
The expression of the PEPCK gene in rat and human small intestine and the effect of streptozotocin-induced diabetes and fasting have been studied using reverse transcriptase-polymerase chain reaction, Northern blot analysis, and determination of enzyme activity.
|
10909974 |
2000 |
|
Diabetes Mellitus
|
0.050 |
Biomarker
|
group |
BEFREE |
PCK1 and PCK2 as candidate diabetes and obesity genes.
|
17709878 |
2007 |
|
Diabetes Mellitus
|
0.050 |
GeneticVariation
|
group |
BEFREE |
To test the hypothesis that mutations of the PEPCK gene promoter contribute to the increased hepatic glucose production that leads to diabetes, we screened for polymorphisms of the PEPCK promoter region in 252 Japanese type 2 diabetic patients and 188 non-diabetic control subjects.
|
12916001 |
2003 |
|
Diabetes Mellitus
|
0.050 |
Biomarker
|
group |
BEFREE |
To employ hepatocytes as surrogate beta-cells for gene therapy of diabetes, a regulatory system was devised in this study by placing the human insulin cDNA under the control of the phosphoenolpyruvate carboxykinase (PEPCK) promoter, followed by the cytomegalovirus immediate early promoter-driven enhanced-green-fluorescent-protein open reading frame.
|
11277867 |
2001 |
|
Liver carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Surprisingly, we found that E1A consistently stimulated basal transcription from the PEPCK promoter in transfection assays in adenovirus (Ad)-infected HepG2 hepatoma cells or E1A-expressing, stably transfected 3T3 fibroblasts and nuclear run-on assays in Ad-infected H4IIE hepatoma cells.
|
8626493 |
1996 |
|
Liver carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Here, we report that the expressions of both PCK1 and PCK2 genes are downregulated in primary hepatocellular carcinoma (HCC) and low PCK expression was associated with poor prognosis in patients with HCC.
|
29335519 |
2018 |
|
Liver carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
In addition, MKP-3 can activate PEPCK promoter in synergy with dexamethasone in hepatoma cells.
|
16126724 |
2005 |
|
Liver carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
SR9009 treatment significantly decreased the mRNA level of Pck1 in mouse hepatoma Hepa-1c1c7 cells, whereas other major enzymes involved in gluconeogenesis (pyruvate carboxylase, glucose-6-phosphatase, fructose bisphosphatase and Pck2) and in glycolysis (phosphofructokinase and hexokinase-1) were unaffected.
|
30639375 |
2019 |